<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568333</url>
  </required_header>
  <id_info>
    <org_study_id>ITP-Low-dose Decitabine</org_study_id>
    <secondary_id>81270578</secondary_id>
    <nct_id>NCT01568333</nct_id>
  </id_info>
  <brief_title>A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia</brief_title>
  <official_title>A Multi-center Study of Low-dose Decitabine for the Treatment of Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decitabine has been reported to have a clinically significant, often long lasting effect on
      the platelet count in myelodysplastic syndromes(MDS). It is also reported that decitabine
      could increase platelet counts by enhancing megakaryocyte maturation and platelet release.
      Immune thrombocytopenia(ITP) is known as an immune-mediated acquired disease characterized by
      transient or persistent decrease of the platelet count. However, refractory ITP is lacking of
      effective treatments and the efficacy of decitabine in ITP remains poorly understood. Data
      from this study may provide some idea of decitabine in the treatment of ITP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are undertaking a multicenter, single-arm study of primary ITP adult
      patients from 9 medical centers in China. All the participants are selected to receive
      low-dose of decitabine treatment (given intravenously at a dose of 3.5mg/m2 for 3 days per
      cycle for 3 cycles). Platelet count, bleeding and other symptoms were evaluated before and
      after treatment. Adverse events are also recorded throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet count</measure>
    <time_frame>the third month after the first dose of decitabine</time_frame>
    <description>plate level at the third month after the first dose of decitabine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding score</measure>
    <time_frame>at enrollment and the third month after the first dose of decitabine</time_frame>
    <description>the assessment of bleeding scores at enrollment and at the third month after the first dose of decitabine</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Decitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.</description>
    <arm_group_label>Decitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult patients with the diagnosis of ITP according to the International Working Group
             (IWG) guidelines

          -  failure to splenectomy or at least four standard ITP-specific treatments, but not
             necessarily undergone splenectomye

          -  baseline peripheral platelet count less than 30,000/uL or the presence of bleeding
             symptoms

          -  need of treatment(s) (including, but not limited to, low dose of corticosteroids) to
             minimize the risk of clinically significant bleeding. Need of on-demand or

        Exclusion Criteria:

          -  secondary ITP

          -  pregnancy

          -  hypertension

          -  cardiovascular disease

          -  diabetes

          -  liver and kidney function impairment

          -  HCV, HIV, HBsAg seropositive status

          -  patients with systemic lupus erythematosus and/or antiphospholipid syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Hou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu hospital, Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shandong University Qilu hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>van den Bosch J, Lübbert M, Verhoef G, Wijermans PW. The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res. 2004 Aug;28(8):785-90.</citation>
    <PMID>15203276</PMID>
  </reference>
  <reference>
    <citation>Wang J, Yi Z, Wang S, Li Z. The effect of decitabine on megakaryocyte maturation and platelet release. Thromb Haemost. 2011 Aug;106(2):337-43. doi: 10.1160/TH10-11-0744. Epub 2011 Jun 28.</citation>
    <PMID>21713321</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>August 17, 2018</last_update_submitted>
  <last_update_submitted_qc>August 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Ming Hou</investigator_full_name>
    <investigator_title>Professor and Director</investigator_title>
  </responsible_party>
  <keyword>Decitabine</keyword>
  <keyword>Immune thrombocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

